A systematic review on the latest developments in testosterone therapy: Innovations, advances, and paradigm shifts

References

• Saad F, Gooren LJ, Haider A, et al. An exploratory study of the effects of 12-month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl. 2007 Nov-Dec;53(6):353–357.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interventions Aging. 2007;2(4):577–590.
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol. 2020;12:1–16.
   Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011 Aug;96(8):2430–2439. Epub 2011 Jun 22. .
   PubMed Web of Science ®Google Scholar
• Yassin A, Haider A, Haider K, et al. TTh in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Cardiovasc Metab Risk. Published. 1 June 2019. DOI:https://doi.org/10.2337/dc18-2388.
   Google Scholar
• Morgunov L, Denisova I, Rozhkova T, et al. Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Skvortsova (2018): hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Aging Male. DOI:https://doi.org/10.1080/13685538.2018.1487932
   Google Scholar
• Haider A, Yassin A, Doros G, et al. Effects of long-term tth on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515.
   PubMed Web of Science ®Google Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45. .
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64–69. Epub 2016 Jan 8. .
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus – a series of case reports. Aging Male. 2015;18(3):164–168.
   PubMed Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Saad F, et al. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. Clin Endocrinol (Oxf). 2016 Jan;84(1):107–114. .
   PubMed Web of Science ®Google Scholar
• Raynaud JP, Gardette J, Rollet J, et al. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int. 2013;111(6):880–890. PSA did not change nor did the incidence of PCa increase significantly while on TRT. It has never been shown that TRT leads to enhanced prostate growth. .
   Web of Science ®Google Scholar
• Khera M, Bhattacharya RK, Blick G, et al. Changes in prostate specific antigen in hypogonadal men after 12 months of Testosteronetherapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005–1011.
   PubMed Web of Science ®Google Scholar
• Ho CC, Tong SF, Low WY, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the aging male symptoms scale. BJU Int. 2012;110(2):260–265.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011;8(7):2079–2089.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–320.
   PubMed Web of Science ®Google Scholar
• Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–2361.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Bruning C, DeWolf W. Occult prostate cancer in men with low serum testosterone levels. Jama. 1996;276:1904–1906.
   PubMed Web of Science ®Google Scholar
• Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015 Jan;193(1):80–86. Epub 2014 Jun 26. PMID: 24980615. .
   PubMed Web of Science ®Google Scholar
• Yassin A, AlRumaihi K, Alzubaidi R, et al. Testosterone, testosterone therapy and prostate cancer. Aging Male. 2018;22(4):219–227.
   Web of Science ®Google Scholar
• Yassin A, Salman M, Talib R, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20(2):125–133.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Rodriguez KM, Nguyen TM, et al. Testosterone therapy and prostate cancer. Transl Androl Urol. 2016;5(6):909–920.
   Web of Science ®Google Scholar
• Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006 Dec;68(6):1263–1267. PMID: 17169647. .
   Web of Science ®Google Scholar
• Morgentaler A, Caliber M. Safety of testosterone therapy in men with prostate cancer. Expert Opin Drug Saf. 2019 Nov;18(11):1065–1076.
   PubMed Web of Science ®Google Scholar
• Yassin A, El-Sakka AI, Saad F, et al. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol. 2008 Aug;26(4):359–364. Epub 2008 Jul 2. .
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Hoesl CE, et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS – implications for clinical practice. Andrologia. 2006;38(38):1–12.
   Google Scholar
• Vignozzi L 1, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012 Jan;212(1):71–84. Epub 2011 Oct 18. .
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin AA, Haider A, et al. Effects of testosterone on the lower urinary tract go beyond the prostate: new insights, new treatment options. Arab J Urol. 2011 Jun;9(2):147–152. Epub 2011 Sep 9. .
   PubMedGoogle Scholar
• Yassin A, Alrumaihi K, Talib R, et al. 186 Voiding function improves under long-term treatment with testosterone undecanoate injections (TU) in hypogonadal men for up to 14 years independent of prostate size. Eur Urol Suppl. 2019;18(1):e253.
   Google Scholar